Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

RenaGel

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2002
2002
BACKGROUND Haemodialysis patients frequently have simultaneous hypercalcemia and hyperphosphatemia, posing a therapeutic dilemma… Expand
2001
2001
Sevelamer hydrochloride (Renagel®) is a nonabsorbed phosphate‐binding polymer marketed for the treatment of hyperphosphatemia in… Expand
2001
2001
Sevelamer hydrochloride (Renagel®) is a nonabsorbed phosphate‐binding polymer approved for the treatment of hyperphosphatemia in… Expand
2001
2001
The effects of sevelamer hydrochloride (Renagel®; hereafter referred to as sevelamer), a noncalcemic phosphate binder, on renal… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
1999
Highly Cited
1999
OBJECTIVE We have previously shown sevelamer hydrochloride (RenaGel) to be an effective and well-tolerated treatment for… Expand
Review
1999
Review
1999
Renagel is a novel, nonabsorbed, phosphate binding polymer free of aluminum and calcium. In hemodialysis patients, Renagel… Expand
Highly Cited
1998
Highly Cited
1998
BACKGROUND Control of dietary phosphate absorption in end-stage renal disease patients is essential to prevent the deleterious… Expand
Highly Cited
1997
Highly Cited
1997
Dietary phosphate restriction and the oral administration of calcium and aluminum salts have been the principal means of… Expand
Highly Cited
1997
Highly Cited
1997
BACKGROUND Available phosphate binders contain aluminium or calcium which can be associated with undesirable effects. RenaGel… Expand
Highly Cited
1997
Highly Cited
1997
BACKGROUND Normalization of serum phosphorus is critical in the treatment of End Stage Renal Failure patients. Aluminum or… Expand